Evolus Inc diskutieren
Evolus Inc
WKN: A2JDYX / Symbol: EOLS / Name: Evolus / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
13,40 €
-2,19 %
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $10.00.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Evolus, Inc. (NASDAQ: EOLS) had its price target raised by analysts at Barclays PLC from $16.00 to $20.00. They now have an "overweight" rating on the stock.
Ratings data for EOLS provided by MarketBeat
Neueste Beiträge
Bank_of_America_Co_ in Hims & Hers Health Inc. diskutieren